Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: A substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial

American Heart Journal

Volumn 159, Issue 1, 2010, Pages 131-140

  Jarai, Rudolf ^a   Huber, Kurt ^a   Bogaerts, Kris ^b   Droogne, Walter ^c   Ezekowitz, Justin ^d   Granger, Christopher B ^e   Sinnaeve, Peter R ^c   Ross, Allan M ^e   Zeymer, Uwe ^f   Armstrong, Paul W ^d   Van de Werf, Frans J ^c  

^a WILHELMINEN HOSPITAL   (Austria)

^b KU LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF ALBERTA   (Canada)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; TENECTEPLASE;

ADULT; AGED; ANGIOPLASTY; ARTICLE; BLOOD CLOT LYSIS; BODY MASS; CARDIOGENIC SHOCK; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; SURVIVAL; SYSTOLIC BLOOD PRESSURE;

AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 72149093529     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.11.001     Document Type: Article

References (36)

1. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115 (2007) e356-e375
2. Jarai R., Wojta J., and Huber K. Circulating B-type natriuretic peptides in patients with acute coronary syndromes. Pathophysiological, prognostical and therapeutical considerations. Thromb Haemost 94 (2005) 926-932
3. Jarai R., Iordanova N., Jarai R., et al. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur Heart J 26 (2005) 250-256
4. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
5. Silver M.A., Maisel A., Yancy C.W., et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10 5 Suppl 3 (2004) 1-30
6. de Lemos J.A., and Morrow D.A. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev Cardiovasc Med 4 Suppl 4 (2003) S37-S46
7. Morrow D.A., Antman E.M., Parsons L., et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 286 (2001) 1356-1359
8. Richards A.M., Nicholls M.G., Yandle T.G., et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart 81 (1999) 114-120
9. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117 (2008) 1936-1944
10. Ezekowitz J.A., Theroux P., Chang W., et al. N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Can J Cardiol 22 (2006) 393-397
11. Sinnaeve P.R., Ezekowitz J.A., Bogaerts K., et al. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. Eur Heart J 30 (2009) 2213-2219
12. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006) 569-578
13. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
14. Jarai R., Iordanova N., Jarai R., et al. Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. Wien Klin Wochenschr 119 (2007) 626-632
15. Frank L.D., Kerr J., Sallis J.F., et al. A hierarchy of sociodemographic and environmental correlates of walking and obesity. Prev Med (2008)
16. Chan F., Cheing G., Chan J.Y., et al. Predicting employment outcomes of rehabilitation clients with orthopedic disabilities: a CHAID analysis. Disabil Rehabil 28 (2006) 257-270
17. Ruff C.T., Wiviott S.D., Morrow D.A., et al. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction. Am J Med 120 (2007) 993-998
18. Morrow D.A., Antman E.M., Charlesworth A., et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102 (2000) 2031-2037
19. Chang W.C., Kaul P., Fu Y., et al. Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. Eur Heart J 27 (2006) 419-426
20. Boden W.E., Eagle K., and Granger C.B. Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol 50 (2007) 917-929
21. Goetze J.P., Christoffersen C., Perko M., et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17 (2003) 1105-1107
22. Weidemann A., Klanke B., Wagner M., et al. Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J 409 (2008) 233-242
23. Goetze J.P., Gore A., Moller C.H., et al. Acute myocardial hypoxia increases BNP gene expression. Faseb J 18 (2004) 1928-1930
24. Hopkins W.E., Chen Z., Fukagawa N.K., et al. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 109 (2004) 2872-2877
25. Morrow D.A., de Lemos J.A., Blazing M.A., et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. Jama 294 (2005) 2866-2871
26. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44 (2004) 1988-1995
27. James S.K., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275-281
28. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
29. Bazzino O., Fuselli J.J., Botto F., et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 25 (2004) 859-866
30. Maioli M., Bellandi F., Leoncini M., et al. Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial). J Am Coll Cardiol 49 (2007) 1517-1524
31. Montalescot G., Borentain M., Payot L., et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 292 (2004) 362-366
32. de Lemos J.A., Antman E.M., Gibson C.M., et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation 101 (2000) 239-243
33. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
34. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
35. Stone G.W., Cox D., Garcia E., et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 104 (2001) 636-641
36. Bruce R.B., Thomas D.S., Charles H., et al. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 85 (2000) 13-18